Teleflex Incorporated filings document the regulatory record for a medical technology issuer with global product categories in anesthesia, emergency medicine, interventional cardiology and radiology, surgery, vascular access and urology. Periodic and current reports disclose operating results, GAAP and non-GAAP measures, revenue adjustments, foreign-currency effects, acquisition and integration items, divestiture-related costs, reserves and other factors affecting reported performance.
Teleflex 8-K filings also cover material events, executive and board transitions, compensation arrangements, shareholder communications, material agreements, capital-structure disclosures and clinical or regulatory matters when reported. Proxy materials disclose director elections, board committee matters, executive compensation, equity awards, pay-versus-performance information and shareholder voting items.
T. Rowe Price Investment Management filed Amendment No. 6 to a Schedule 13G/A reporting 3,836,207 shares of Teleflex Inc. common stock, equal to 8.7% of the class. The filing lists 3,824,270 shares of sole voting power and 3,836,207 shares of sole dispositive power.
The filing also expressly states that the filer "hereby declares and affirms that the filing of shall not be construed as an admission that Price Investment Management is the beneficial owner" of the securities. Signature on the amendment is dated 05/15/2026.
Teleflex interim President and CEO Stuart A. Randle reported a routine tax-related share disposition. On the vesting of a restricted stock unit award, 289 shares of Common Stock were withheld at $133.06 per share to cover tax liabilities, leaving him with 19,583 shares held directly.
Teleflex grew first-quarter 2026 net revenues to $548.3 million, up 32.3% from a year earlier, driven mainly by the acquired BIOTRONIK Vascular Intervention business and higher volumes of existing products. Despite this growth, gross margin fell to 56.1% from 61.7% due to 2025 tariffs, acquisition-related amortization, quality and inventory costs, and higher logistics expenses.
The company reported a net loss of $8.2 million, compared with net income of $95.0 million a year ago, as selling, general and administrative and research and development expenses rose with the VI Business, restructuring programs and CEO severance. Discontinued operations tied to planned divestitures of the Acute Care, Interventional Urology and OEM businesses also shifted from a $42.7 million profit to a $3.3 million loss, including a $29.0 million valuation allowance. Teleflex expects $2.0 billion in cash proceeds from these sales and plans to use about $1.8 billion of net after-tax proceeds mainly for share repurchases and debt reduction.
Teleflex Incorporated reported mixed first-quarter 2026 results from continuing operations. Revenue reached $548.3 million, up 32.3% year-over-year and 5.1% on a pro forma adjusted constant currency basis, reflecting growth across Vascular Access, Interventional and Surgical categories.
GAAP diluted EPS from continuing operations was a loss of $(0.11), down from earnings of $1.14, driven by higher costs including restructuring, acquisition and amortization charges. Adjusted diluted EPS from continuing operations was $1.39, slightly below $1.44 a year earlier.
The company maintained its 2026 outlook, guiding to GAAP revenue growth of 14.40%–15.40%, pro forma adjusted constant currency revenue growth of 4.50%–5.50%, GAAP EPS of $2.90–$3.20 and adjusted EPS of $6.25–$6.55. Guidance includes about $90 million of stranded costs and excludes benefits from transition and manufacturing services agreements, planned ~$800 million debt reduction and a $1 billion share repurchase program funded largely by pending divestitures. Teleflex expects its Acute Care, Interventional Urology and OEM Strategic Divestitures to close in the second half of 2026 and has appointed Jason Weidman as President and CEO effective June 8, 2026.
Teleflex Incorporated appointed Jason Weidman as its new President and Chief Executive Officer, effective June 8, 2026, succeeding interim CEO Stuart Randle, who will remain on the Board. The Board also expects to appoint Mr. Weidman as a director when he starts.
Mr. Weidman joins from Medtronic, where over nearly two decades he led large coronary, renal denervation, aortic, peripheral and venous businesses and oversaw global growth, product launches and acquisitions. His compensation package includes a $1 million base salary, a target annual bonus equal to 125% of salary and a $7 million annual equity award target beginning in 2027.
The offer includes a $7 million sign-on restricted stock grant and $1 million in stock options with multi‑year vesting, an up to $800,000 cash payment to replace forfeited incentives, relocation benefits and robust severance and change‑of‑control protections. In the company’s accompanying statement, the Chair highlighted Teleflex’s focus on core interventional and critical care markets and referenced an intended $1 billion share buyback and $800 million debt paydown following the close of pending sale transactions.
Teleflex Inc ownership update: Vanguard Capital Management reports beneficial ownership of 2,324,576 shares of Common Stock, representing 5.25% of the class. The filing states sole voting power for 340,752 shares and sole dispositive power for 2,324,576 shares. The filing attributes these holdings to Vanguard Capital Management and specified Vanguard affiliates and notes that some shares are held on behalf of Vanguard funds and managed accounts.
Teleflex Inc Schedule 13G: Vanguard Portfolio Management reports beneficial ownership of 2,458,623 shares of Teleflex common stock as of 03/31/2026, representing 5.56% of the class. The filing shows sole dispositive power for 2,458,623 shares and sole voting power for 20,440 shares. The form is signed by Ashley Grim on 04/29/2026.
Teleflex Inc corporate vice president Dominik Michal Reterski filed an initial ownership report, showing direct holdings of common stock, stock options and restricted stock units in Teleflex.
He holds 7,198 shares of common stock directly plus multiple stock option grants and RSU awards that vest over several years, contingent on continued service.
Teleflex Incorporated is asking stockholders to vote at its May 15, 2026 annual meeting on four items: electing seven directors for one-year terms, approving executive pay on an advisory basis, ratifying PricewaterhouseCoopers LLP as auditor, and handling other routine business.
The proxy details an actively refreshed, mostly independent board, including a new nominee, Michael J. Tokich, and an independent chair structure. It highlights Teleflex’s 2025 portfolio transformation, including acquiring BIOTRONIK’s Vascular Intervention business and signing agreements to sell the Acute Care, Interventional Urology and OEM units. These divestitures are expected to generate about $1.8 billion in after-tax proceeds, supporting a planned $1.0 billion share repurchase and $800 million of debt reduction.
The filing also explains governance practices, stockholder engagement, updated director compensation, and an executive pay program emphasizing performance-based incentives, stock ownership guidelines and clawback provisions. It notes CEO transitions, an ongoing search for a permanent chief executive, and design changes to performance stock units tied to absolute total shareholder return.